Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy

被引:121
作者
Lorenzo, JA
Naprta, A
Rao, Y
Alander, C
Glaccum, M
Widmer, M
Gronowicz, G
Kalinowski, J
Pilbeam, CC
机构
[1] VA Connecticut Healthcare Syst, Newington, CT 06111 USA
[2] Univ Connecticut, Ctr Hlth, Dept Med, Farmington, CT 06030 USA
[3] Univ Connecticut, Ctr Hlth, Dept Orthoped, Farmington, CT 06030 USA
[4] Immunex Res & Dev Corp, Seattle, WA 98101 USA
关键词
D O I
10.1210/en.139.6.3022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We measured the effects of ovariectomy on the bone mass of mice that lacked type I interleukin-1 receptor (IL-1 R1 -/- mice) in two genetic backgrounds (C57BL/6 x 129/Sv and C57BL/6) to investigate the role of interleukin-1 in the actions of estrogen on bone. At three weeks after surgery, ovariectomized wild-type mice decreased trabecular bone volume in the proximal humerus by 70% in a C57BL/6 x 129/Sv background and 48% in a C57BL/6 background compared to sham-operated controls. In contrast, there was no significant decrease in trabecular bone mass in IL-1 R1 -/- mice after ovariectomy. The estrogen status of all groups was confirmed by measurement of uterine wet weight. These results demonstrate that a functional IL-1 response pathway is required for mice to lose trabecular bone mass after ovariectomy in this model and they imply that IL-1 is an important mediator of the effects of ovariectomy on bone mass. Hence, therapeutic interventions that block the effects of IL-1 on bone may be beneficial for treating diseases of rapid bone loss such as post-menopausal osteoporosis.
引用
收藏
页码:3022 / 3025
页数:4
相关论文
共 20 条
[1]   Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency [J].
Ammann, P ;
Rizzoli, R ;
Bonjour, JP ;
Bourrin, S ;
Meyer, JM ;
Vassalli, P ;
Garcia, I .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (07) :1699-1703
[2]  
Bancroft J.D., 1990, THEORY PRACTICE HIST, P379
[3]   THE TYPE-II DECOY RECEPTOR - A NOVEL REGULATORY PATHWAY FOR INTERLEUKIN-1 [J].
COLOTTA, F ;
DOWER, SK ;
SIMS, JE ;
MANTOVANI, A .
IMMUNOLOGY TODAY, 1994, 15 (12) :562-566
[4]   INTERLEUKIN-1 TYPE-II RECEPTOR - A DECOY TARGET FOR IL-1 THAT IS REGULATED BY IL-4 [J].
COLOTTA, F ;
RE, F ;
MUZIO, M ;
BERTINI, R ;
POLENTARUTTI, N ;
SIRONI, M ;
GIRI, JG ;
DOWER, SK ;
SIMS, JE ;
MANTOVANI, A .
SCIENCE, 1993, 261 (5120) :472-475
[5]  
DINARELLO CA, 1991, BLOOD, V77, P1627
[6]  
Glaccum MB, 1997, J IMMUNOL, V159, P3364
[7]   CYTOKINES AND ESTROGEN IN BONE - ANTI-OSTEOPOROTIC EFFECTS [J].
HOROWITZ, MC .
SCIENCE, 1993, 260 (5108) :626-627
[8]   OVARIECTOMY ENHANCES AND ESTROGEN REPLACEMENT INHIBITS THE ACTIVITY OF BONE-MARROW FACTORS THAT STIMULATE PROSTAGLANDIN PRODUCTION IN CULTURED MOUSE CALVARIAE [J].
KAWAGUCHI, H ;
PILBEAM, CC ;
VARGAS, SJ ;
MORSE, EE ;
LORENZO, JA ;
RAISZ, LG .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (01) :539-548
[9]  
Luna L.G., 1968, MANUAL HISTOLOGIC ST
[10]   MECHANISMS OF DISEASE - BONE-MARROW, CYTOKINES, AND BONE REMODELING - EMERGING INSIGHTS INTO THE PATHOPHYSIOLOGY OF OSTEOPOROSIS [J].
MANOLAGAS, SC ;
JILKA, RL .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (05) :305-311